Bringing MDMA-assisted therapy for PTSD to traditional healthcare systems: tending to set and setting.
Dimitri Perivoliotis, Kayla Knopp, Shannon Remick, Allie Kaigle, Christopher S Stauffer, Chandra Khalifian, Tamara R Wachsman, Bettye E Chargin, Andrew W Bismark, Al Alam, Leslie Morland
Frontiers in psychiatry January 1, 2025 DOI: 10.3389/fpsyt.2025.1433999 via PubMed
Summary
AI-generated from the abstractSet and setting—the mindset a person brings to therapy and the environment in which it occurs—are foundational to MDMA-assisted therapy for PTSD and critically influence its efficacy. Drawing on experience conducting clinical trials in the Veterans Health Administration, this article describes advantages and challenges of implementing this intervention in large healthcare systems. Specific, practical suggestions are offered for optimizing set and setting from both participant and clinician perspectives, aiming to leverage opportunities and adapt to challenges. These recommendations are intended to inform future research and potential clinical implementation efforts in traditional healthcare settings.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Intervention | MDMA-assisted therapy |
| Topics | MDMA PTSD |
| Keywords | MDMA-Assisted Therapy Implementation Psychedelics #PTSD-Treatment PTSD Therapy Trauma therapy |
| Citations | 2 |
| Key finding | Set and setting are critical to the efficacy of MDMA-assisted therapy for PTSD, and implementing this therapy in large healthcare systems like the VHA requires optimizing these factors from both participant and clinician perspectives. |
Abstract
Although effective evidence-based trauma-focused psychotherapies for posttraumatic stress disorder (PTSD) are available, a significant proportion of patients show a suboptimal response or do not complete them. MDMA-assisted therapy (MDMA-AT) for PTSD is a promising intervention currently being evaluated in numerous studies worldwide, including investigation for potential Food and Drug Administration (FDA) approval in the United States. The concepts of set and setting are foundational in psychedelic therapy and refer to the mindset a person brings to therapy and the environment in which it takes place, respectively. Both are believed to play a critical role in the individual's experience and efficacy of MDMA-AT. In this article, we describe the importance of set and setting in MDMA-AT for PTSD and outline the advantages and challenges of implementing this novel intervention in large healthcare settings such as the Veterans Health Administration (VHA). Mostly derived from our experience conducting clinical trials of MDMA-AT for PTSD in VHA, we present specific and practical suggestions for optimizing set and setting from both the participant's and clinician's perspective in a manner that both leverages the opportunities of such settings and adapts to their challenges. These recommendations are intended to inform future MDMA-AT for PTSD research and, potentially, eventual clinical implementation efforts in traditional healthcare systems.